PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
Professor Thomas Powles, MBBS, MRCP, MD - Examining the State of the Science on New Therapies in Bladder Cancer: Perspectives on the Latest Developments Across the Disease Continuum
Go online to PeerView.com/ECU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology discuss real-world applications of emerging data and innovative therapeutics, offering practical strategies for developing sound, evidence-based protocols to provide more potent and effective treatment options to patients with bladder cancer. Upon completion of this activity, participants should be better able to: Describe when and how novel therapeutic agents in advanced bladder cancer can be used over multiple lines of treatment and across patient populations, Cite the latest safety and efficacy data on newer therapies, including immune checkpoint inhibitors, targeted agents, antibody-drug conjugates and gene therapy across the spectrum of bladder cancer settings, Select novel therapeutics for the management of bladder cancer based on patient-related factors and preferences, Develop appropriate management plans that take into account unique adverse events associated with new immune-, targeted-, and antibody-, and gene therapy-based treatments for bladder cancer.
Robert Dreicer, MD, MS, MACP, FASCO - Making the Right Moves in the Evolving Prostate Cancer Therapeutic Landscape: Expert Guidance on Treatment Sequencing and Selection for Effective Management Across the Disease Continuum
Go online to PeerView.com/BCF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. A new, expert-led MasterClass from PeerView and the Us TOO International Prostate Cancer Education & Support Network will provide guidance on individualizing treatment regimens for patients with prostate cancer and will address the latest clinical evidence and guidelines/expert consensus recommendations. The program will also offer information on relevant patient-, tumor-, and treatment-related factors, as well as how to handle patients’ specific needs and preferences. Upon completion of this activity, participants should be better able to: Review recent safety and efficacy data of emerging and available agents across the prostate cancer disease continuum (nmCRPC, mCSPC, mCRPC), including the latest evidence and expert recommendations for selection and sequencing of approved hormonal and chemotherapy options, Outline the latest clinical evidence for appropriate use of novel therapies (eg, PARP inhibitors and immunotherapy) in mCRPC, including monotherapy and combination approaches, Evaluate the latest genetic testing guidelines to better direct treatment decision-making throughout the prostate cancer disease continuum, Develop evidence-based, tailored treatment plans, including the option of clinical trial enrollment, for patients with prostate cancer, based on disease-, patient-, and treatment-specific factors.
Titte R. Srinivas, MD, FAST - Optimizing Maintenance Immunosuppressive Therapy in Kidney Transplantation: Examining Current and Future Strategies to Preserve Graft Function and Maximize Long-Term Outcomes
Go online to PeerView.com/SDN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in nephrology discusses evidence-based strategies to individualize immunosuppressive therapy and optimize long-term outcomes after renal transplantation. Upon completion of this activity, participants should be better able to: Identify risk factors for graft loss and mortality after renal transplantation, Recognize the benefits and limitations of current immunosuppressive strategies used to prevent acute rejection and promote long-term graft survival after renal transplantation, Apply evidence-based approaches to optimize maintenance immunosuppressive therapy in individual kidney transplant recipients, recognizing how and when to initiate CNI-sparing strategies, Describe emerging strategies to prolong the durability of transplanted kidneys as well as potentially improve long-term outcomes for kidney transplant patients.
Neal D. Shore, MD, FACS - Changing the Treatment Story With Hormonal Therapy in Prostate Cancer: Challenges and Opportunities for Improving Care Across Disease Settings
Go online to PeerView.com/QAT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in urologic oncology discusses hormonal therapy in prostate cancer. Upon completion of this activity, participants should be better able to: Summarize the recent safety and efficacy data on novel hormonal therapy for metastatic castration-sensitive prostate cancer (mCSPC), as well as for other prostate cancer settings including castration-resistant (nmCRPC and mCRPC) disease, Counsel patients on current hormonal therapy standards for personalized management of prostate cancer, including for treatment selection based on disease progression, prior therapy, and patient characteristics, Design individualized, evidence-based treatment plans for patients with prostate cancer, taking into consideration disease, treatment, and patient-specific factors, Manage the spectrum of adverse events associated with novel hormonal therapies in patients with prostate cancer.
William K. Oh, MD - Understanding the Evolving Treatment Landscape in Prostate Cancer: How to Leverage the Latest Advances and Strategies to Optimize Patient Outcomes
Go online to PeerView.com/DRP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This unique activity pairs the latest evidence with clinical decision points on key issues that may arise in managing patients with early- and late-stage prostate cancer. The expert-led Seminars and Tumor Board will support discussions of several practical aspects of applying ADT, PARP inhibitors, and immunotherapies in prostate cancer management and highlight how clinicians can ensure timely incorporation of evidence-based recommendations to improve individual patient outcomes. Upon completion of this activity, participants should be better able to: Describe the latest guideline recommendations for managing both early and advanced prostate cancer and associated treatment selection factors, including disease progression, prior therapy, and patient characteristics, Outline the most recent clinical data and expert recommendations for therapy selection and sequencing as monotherapy or in combination in the non-metastatic and metastatic prostate cancer settings, Assess safety and efficacy findings for novel, emerging, and existing therapeutic agents, Design individualized, evidence-based treatment plans that may include clinical trial enrollment for patients with prostate cancer, taking into consideration disease, treatment, and patient-specific factors.
George L. Bakris, MD - Improving Outcomes and Preventing Chronic Kidney Disease Progression: Evaluating the Role of Novel Nonsteroidal Mineralocorticoid Receptor Antagonists
Go online to PeerView.com/CWT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in nephrology discuss emerging evidence for improving outcomes and preventing chronic kidney disease (CKD) progression using nonsteroidal mineralocorticoid receptor antagonists. Upon completion of this activity, participants should be better able to: Apply current guidance consistent with the latest recommendations for screening, diagnosis, and treatment of patients with or at risk of developing CKD, Describe the interrelationships among CKD and other common cardiometabolic comorbidities, Evaluate the role and clinical potential of novel nonsteroidal mineralocorticoid receptor antagonists in providing renoprotection and preventing disease progression in patients diagnosed with CKD.